Stories on the discovery of vital fluid-transport systems in the human body are among the winners of the 2024 AAAS Kavli Science Journalism Awards. Winning journalists also did immersive stories on ...

AstraZeneca shared the topline result from the placebo-controlled trial in a press release Tuesday. NF1 affects around 1.7 million people worldwide, with about 70% being adults, according to ...

LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of lung cancer, a step that will delay the drug’s arrival on the ...

LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million pounds ($576.7 million) in Britain for vaccine research and development ...

AstraZeneca has put a £450m investment in Britain under review in a stand-off with ministers over state aid. The drugs giant told The Telegraph that proposals to build a new vaccine factory in ...

British drugmaker AstraZeneca increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the ...

Top of the morning to you. And a fine one it is. Lots of sunshine and clear blue skies are once again enveloping the Pharmalot campus, where the official mascots are bounding about the grounds in ...

Not too long ago, pharmaceutical giant Astrazeneca reached a £200bn valuation—one of only a few London-listed FTSE 100 companies to do so. The major milestone was a testament to CEO Pascal ...

AstraZeneca CEO Pascal Soriot argued that the company did not lose oversight. “You really cannot police 18,000 people from the headquarter,” Soriot said during a press call Tuesday ...

AstraZeneca said it is in China ‘for the long haul’ and outlined billions of pounds of investment in the US – but a new vaccine factory in the UK hangs in the balance. The pharma giant’s ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid a probe that has battered the drugmaker’s share price. Chief ...

In a report released today, Rajan Sharma from Goldman Sachs maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of £160.46. The company’s shares opened today ...